Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019
Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019
SUMMARY
According to the recently published report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019'; Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Cathepsin S (CTSS or EC 3.4.22.27) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.
The report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology, Infectious Disease and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
SCOPE
SUMMARY
According to the recently published report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019'; Cathepsin S (CTSS or EC 3.4.22.27) pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes.
Cathepsin S (CTSS or EC 3.4.22.27) - Cathepsin S is a lysosomal enzyme that belongs to the papain family of cysteine proteases. Cathepsin S has a role in itch and pain, or nociception. The nociceptive activity results from cathepsin S functioning as a signaling molecule via activation of protease-activated receptors 2 and 4 members of the G-protein coupled receptor family. Cathepsin S has a physiological role outside the lysosome. Immune cells, including macrophages and microglia, secrete cathepsin S in response to inflammatory mediators including lipopolysaccharides, proinflammatory cytokines and neutrophils.
The report 'Cathepsin S (CTSS or EC 3.4.22.27) - Pipeline Review, H2 2019' outlays comprehensive information on the Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.
It also reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase 0, Preclinical and Discovery stages are 1, 4 and 1 respectively. Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Central Nervous System, Oncology, Gastrointestinal, Immunology, Infectious Disease and Metabolic Disorders which include indications Alzheimer's Disease, Autoimmune Disorders, Breast Cancer, Cancer Pain, Chagas Disease (American Trypanosomiasis), Colorectal Cancer, Diabetic Retinopathy, Glioblastoma Multiforme (GBM), Liver Fibrosis, Neuropathic Pain (Neuralgia), Pancreatic Cancer, Primary Biliary Cholangitis (Primary Biliary Cirrhosis) and Prostate Cancer.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Cathepsin S (CTSS or EC 3.4.22.27)
- The report reviews Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics and enlists all their major and minor projects
- The report assesses Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Cathepsin S (CTSS or EC 3.4.22.27) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Cathepsin S (CTSS or EC 3.4.22.27)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Cathepsin S (CTSS or EC 3.4.22.27) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Cathepsin S (CTSS or EC 3.4.22.27) - Overview
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development
Evotec SE
F. Hoffmann-La Roche Ltd
Fusion Antibodies Plc
Virobay Inc
Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles
Fsn-0503h - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5461111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cathepsin S for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-50365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Products
Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products
Cathepsin S (CTSS or EC 3.4.22.27) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Cathepsin S (CTSS or EC 3.4.22.27) - Overview
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Cathepsin S (CTSS or EC 3.4.22.27) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Cathepsin S (CTSS or EC 3.4.22.27) - Companies Involved in Therapeutics Development
Evotec SE
F. Hoffmann-La Roche Ltd
Fusion Antibodies Plc
Virobay Inc
Cathepsin S (CTSS or EC 3.4.22.27) - Drug Profiles
Fsn-0503h - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RO-5461111 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
SAR-114137 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Inhibit Cathepsin S for Oncology - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-285 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-50365 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
VBY-825 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Cathepsin S (CTSS or EC 3.4.22.27) - Dormant Products
Cathepsin S (CTSS or EC 3.4.22.27) - Discontinued Products
Cathepsin S (CTSS or EC 3.4.22.27) - Product Development Milestones
Featured News & Press Releases
Jul 27, 2015: NIH helps UC San Diego researchers repurpose Sanofi pain drug for tropical disease
Nov 14, 2014: Virobay To Present Data On Two Cathepsin S Inhibitor Programs In Neuropathic Pain And Alzheimer's Disease At The 2014 Society For Neuroscience Annual Meeting
Nov 14, 2011: Virobay's Spectrum-Selective Cathepsin Inhibitor Shows Efficacy In Bone Cancer Model
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Fusion Antibodies Plc, H2 2019
Pipeline by Virobay Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Indication, H2 2019
Number of Products under Development by Companies, H2 2019
Products under Development by Companies, H2 2019
Number of Products under Investigation by Universities/Institutes, H2 2019
Products under Investigation by Universities/Institutes, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Stage and Molecule Type, H2 2019
Pipeline by Evotec SE, H2 2019
Pipeline by F. Hoffmann-La Roche Ltd, H2 2019
Pipeline by Fusion Antibodies Plc, H2 2019
Pipeline by Virobay Inc, H2 2019
Dormant Products, H2 2019
Dormant Products, H2 2019 (Contd..1), H2 2019
Discontinued Products, H2 2019
LIST OF FIGURES
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Evotec SE
F. Hoffmann-La Roche Ltd
Fusion Antibodies Plc
Virobay Inc
Number of Products under Development by Stage of Development, H2 2019
Number of Products under Development by Therapy Areas, H2 2019
Number of Products under Development by Top 10 Indications, H2 2019
Number of Products by Stage and Mechanism of Actions, H2 2019
Number of Products by Stage and Route of Administration, H2 2019
Number of Products by Molecule Types, H2 2019
Number of Products by Stage and Molecule Types, H2 2019
COMPANIES MENTIONED
Evotec SE
F. Hoffmann-La Roche Ltd
Fusion Antibodies Plc
Virobay Inc
